Aflibercept
- TRADE NAMES: Eylea (Regeneron); Zaltrap (Sanofi-Aventis)
- INDICATIONS: Neovascular (wet) age-related macular degeneration (Eylea); metastatic colorectal cancer (Zaltrap) in combination with FOLFIRI (fluorouracil, leucovorin and irinotecan)
- SYNONYM: ziv-aflibercept
- CLASS: Angiogenesis inhibitor, Fusion protein, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: terminal 5–6 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
PREGNANCY CATEGORY: C
Eylea: Contra-indicated in patients with ocular or periocular infection or active intraocular inflammation.
Zaltrap: HEMORRHAGE, GASTROINTESTINAL PERFORATION, COMPROMISED WOUND HEALING
See full prescribing information for complete boxed warning
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 11/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
